CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myelomaJames R. Berenson, Jesús G. Berdeja, Morton Coleman et al.|Blood|2016Cited by 94
Oprozomib and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma: Initial Results from the Dose Escalation Portion of a Phase 1b/2, Multicenter, Open-Label StudyParameswaran Hari, Claudia Prada, Kenneth H. Shain et al.|Blood|2014Cited by 18
Updated results from CHAMPION-1, a phase I/II study investigating weekly carfilzomib with dexamethasone for patients (Pts) with relapsed or refractory multiple myeloma (RRMM).James R. Berenson, Jesús G. Berdeja, Alan Cartmell et al.|Journal of Clinical Oncology|2015Cited by 4
Weekly Carfilzomib with Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma: Updated Results from the Phase 1/2 Study Champion-1 (NCT01677858)James R. Berenson, Jesús G. Berdeja, Alan Cartmell et al.|Blood|2015Cited by 4